Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Steven Coutré(Georgetown University), Matthew S. Davids(Dana-Farber Cancer Institute), Rod Humerickhouse(Abbott Fund), Brenda Chyla(AbbVie (United States)), Suresh Agarwal(Boston Medical Center), Herbert Eradat(University of Colorado Cancer Center), Tina Waskiewicz(AbbVie (United States)), Michael Y. Choi(University of California San Diego), William G. Wierda(University of Maryland, Baltimore), Jalaja Potluri(AbbVie (United States)), Jeffrey A. Jones(The Ohio State University), Leonard T. Heffner, Richard R. Furman(Cornell University), Maria Verdugo(AbbVie (United States)), Lang Zhou(Qingdao University)
Cited by 132
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k